Atroxlysin-III, A Metalloproteinase from the Venom of the Peruvian Pit Viper Snake Bothrops atrox (Jergón) Induces Glycoprotein VI Shedding and Impairs Platelet Function [PDF]
Molecules, 2019 Atroxlysin-III (Atr-III) was purified from the venom of Bothrops atrox. This 56-kDa protein bears N-linked glycoconjugates and is a P-III hemorrhagic metalloproteinase.
Luciana S. Oliveira +8 more
doaj +2 more sources
Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation. [PDF]
PLoS ONE, 2021 Platelets can respond to multiple antagonists and agonists, implying that their activation state is a consequence of past exposure to these substances.
Jinmi Zou +3 more
doaj +2 more sources
Quantitative Characterization of Shear-Induced Platelet Receptor Shedding: Glycoprotein Ibα, Glycoprotein VI, and Glycoprotein IIb/IIIa. [PDF]
ASAIO J, 2018 The structural integrity of platelet receptors is essential for platelets to play the normal hemostatic function. The high non-physiologic shear stress (NPSS) commonly exists in blood-contacting medical devices and has been shown to cause platelet receptor shedding.
Chen Z +4 more
europepmc +4 more sources
Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore? [PDF]
Arterioscler Thromb Vasc Biol, 2020 Gupta S, Brass LF.
europepmc +4 more sources
Glycoprotein VI in securing vascular integrity in inflamed vessels. [PDF]
Res Pract Thromb Haemost, 2018 Glycoprotein VI (GPVI), the main platelet receptor for collagen, has been shown to play a central role in various models of thrombosis, and to be a minor actor of hemostasis at sites of trauma. These observations have made of GPVI a novel target for antithrombotic therapy, as its inhibition would ideally combine efficacy with safety.
Boulaftali Y +3 more
europepmc +4 more sources
ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundGPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies.
Heidrun Degen +14 more
doaj +2 more sources
Is glycoprotein VI involved in contractual negotiations? [PDF]
Res Pract Thromb HaemostBrysland SA, Hearn JI, Gardiner EE.
europepmc +3 more sources
Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism [PDF]
Haematologica, 2020 Hanne Skille +9 more
doaj +2 more sources
Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs. [PDF]
Eur Heart JMangin PH, Jandrot-Perrus M.
europepmc +3 more sources
Haematologica, 2021 Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes.
Martina H. Lundberg Slingsby +14 more
doaj +1 more source